Indonesia vs United Arab Emirates: Share of S. aureus infections resistant to methicillin
Indonesia
35.2%
in 2022
United Arab Emirates
39.9%
in 2022
Indonesia rank
16th
United Arab Emirates rank
15th
Share of S. aureus infections resistant to methicillin over time
- Indonesia
- United Arab Emirates
How they compare
United Arab Emirates currently reports 39.9% against 35.2% in Indonesia, a difference of 4.7%.
That makes United Arab Emirates's figure about 1.1 times Indonesia's.
The two have swapped places 3 times across 5 shared years of data; in 2018 it was Indonesia ahead.
Indonesia ranks 16th and United Arab Emirates ranks 15th of 45 countries.
Across the 2 decades both report, Indonesia averaged higher in 1 and United Arab Emirates in 1.
Head to head by decade
| Decade | Indonesia | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 46.1% | 30.0% | 16.1% | Indonesia |
| 2020s | 36.4% | 39.4% | 3.0% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Indonesia or United Arab Emirates?
- United Arab Emirates, at 39.9% against 35.2% in Indonesia as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Indonesia and United Arab Emirates?
- 4.7%, with United Arab Emirates ahead.
- How many years of comparable data are there for Indonesia and United Arab Emirates?
- 5 years are reported by both, from 2018 to 2022.
- How do Indonesia and United Arab Emirates rank globally for share of s. aureus infections resistant to methicillin?
- Indonesia ranks 16th and United Arab Emirates ranks 15th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).